Background Imported cases of infectious disease provide invaluable information about
epidemiological conditions abroad, and should guide treatment decisions at home and …

Background Anti-malarial drug resistance is a severe challenge for eventual control and
global elimination of malaria. Resistance to sulfadoxine-pyrimethamine (SP) increases as …

We evaluated markers of sulfadoxine-pyrimethamine (SP) resistance in Plasmodium
falciparum among 254 returned migrant workers in China from Africa from 2013 to 2016 …

Background Malaria is a major parasitic disease, affecting millions of people in endemic
areas. Plasmodium falciparum parasites are responsible for the most severe cases and its …

Background Malawi experienced prolonged use of sulfadoxine/pyrimethamine (SP) as the
front-line anti-malarial drug, with early replacement of chloroquine and delayed introduction …

Background Sulfadoxine–pyrimethamine (SP) is a cornerstone of malaria chemoprophylaxis
and is considered for programmes in the Democratic Republic of Congo (DRC). However …

The global spread of sulfadoxine (Sdx, S) and pyrimethamine (Pyr, P) resistance is attributed
to increasing number of mutations in DHPS and DHFR enzymes encoded by malaria …

Background While malaria incidence in Indonesia has decreased threefold in the last
decade, more than 200,000 cases were reported in 2016. Different endemicity of …

Background Sulfadoxine-pyrimethamine (SP) is recommended for intermittent preventive
treatment in Africa against Plasmodium falciparum infection. However, increasing SP …

Background Anti-malarial drug resistance remains a key concern for the global fight against
malaria. In Ghana sulfadoxine-pyrimethamine (SP) is used for intermittent preventive …